Skip to main content

Table 4 Summary of clinical outcomes stratified by group.

From: Clinical characteristics and outcomes of patients with acute myelogenous leukemia admitted to intensive care: a case-control study

Outcome Total
(n = 145)
AML ICU Cases
(n = 45)
AML non-ICU Controls
(n = 50)
Non-AML ICU Controls
(n = 225)
p-value
ICU death (%) 83 (30.7) 17 (37.8) - 66 (29.3) 0.29
Hospital death (%) 121 (37.8) 20 (44.4) 9 (18.0) 92 (40.9) 0.004
28-Day death (%) 98 (30.6) 17 (37.8) 8 (16.0) 73 (32.4) 0.03
90-Day death (%) 132 (41.3) 23 (51.1) 16 (32.0) 93 (41.3) 0.17
1-Year death (%) 178 (55.6) 32 (71.1) 27 (54.0) 119 (52.9) 0.08
ICU length of stay (days) 4 (2-11) 5 (2-12) - 4 (2-11) 0.38
   Survived 5 (2-12) 8 (2-14) - 5 (3-11) 0.44
   Dead 2 (1-5) 4 (1-7) - 1 (1-3) 0.17
Hospital length of stay (days) 15 (6-39) 22 (11-47) 24 (9-35) 13 (5-36) 0.12
   Survived 21 (10-45) 37 (18-50) 25 (12-35) 17 (10-44) 0.22
   Dead 14 (9-28) 13 (9-19) 6 (1-28) 3 (1-12) 0.17
Median survival (95% CI) (days) 207 (14-2442) 82 (14-700) 274 (55-1303) 258 (9-2442) 0.01